Nivolumab after Induction Chemotherapy in Previously Treated Non-Small-Cell Lung Cancer Patients with Low PD-L1 Expression

SIMPLE SUMMARY: Different strategies have been explored to counteract immune evasion by shifting the balance in favor of antitumor immune activation, and combination cytotoxic chemotherapies have emerged as potent immune modulators for patients with low programmed death-ligand 1 expression. This stu...

Descripción completa

Detalles Bibliográficos
Autores principales: Ahn, Beung-Chul, Park, Charny, Lee, Sang-Jin, Hong, Sehwa, Hwang, Ji-Eun, Kwon, Kyoungsuk, Kim, Jin Young, Kim, Kyung-Hee, Kim, Hyae Young, Lee, Geon Kook, Lee, Youngjoo, Han, Ji-Youn
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10526182/
https://www.ncbi.nlm.nih.gov/pubmed/37760429
http://dx.doi.org/10.3390/cancers15184460

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10526182/
https://www.ncbi.nlm.nih.gov/pubmed/37760429
http://dx.doi.org/10.3390/cancers15184460

Ejemplares similares